Navigation Links
CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients

Wireless Device Provides Comprehensive Clinical Picture, Improves Patient-Physician Communications

KING OF PRUSSIA, Pa., Aug. 25 /PRNewswire/ -- Hemophilia A patients who use Helixate(R) FS, Antihemophilic Factor (Recombinant), and their treatment providers are now tracking treatment progress in real time, thanks to the HeliTraxSM System, a state-of-the-art wireless Internet-based data management system recently introduced by CSL Behring. The system allows for a comprehensive view of a patient's progress, with young patients relaying information about bleeding events and their use of Helixate FS to their hemophilia treatment center via the handheld device between office visits. The HeliTrax System, used in conjunction with Helixate FS treatment, is designed to improve patient-physician communications and therapy management.

"HeliTrax provides clinicians with the rapid, comprehensive clinical view they need to make assessments about treatment, it eliminates paperwork and helps to streamline patient data management," says Jill Leone, RN, CCRP, a hematology nurse who helped develop the system. "For young patients, HeliTrax helps them keep in touch with their therapy and motivates them to stay on track."

Physicians monitoring hemophilia A patients previously relied on paper forms filled out by the patients or their caregivers, which did not always provide necessary clinical information in a timely, clear and concise way. HeliTrax not only tracks a patient's therapy as it happens -- including medication usage and inventory -- but allows the hemophilia treatment center to generate a one-page, easy-to-read, full-color clinical report of the patient's progress. These private, secure reports, which help reduce documentation and transcription errors, are compliant with both the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and the Health Insurance Portability and Accountability Act (HIPAA). Additionally, the system is backed up every 48 hours, ensuring that the patient's complete record is saved. CSL Behring has no access to patient data and all data are managed by a third-party company.

HeliTrax is also equipped with a camera to document bleeding events. Patients can quickly capture a high-quality picture of the bleed, which can then be seamlessly transmitted electronically to their treatment team, who can assess the seriousness of the event and often save the patient from making unnecessary trips to the emergency room.

"This innovative device uses cutting-edge technology to help those living with a bleeding disorder to manage their condition," said Garrett E. Bergman M.D., Senior Director of U.S. Medical Affairs at CSL Behring. "CSL Behring is committed to the bleeding disorder community and continues to develop creative management tools with the patient in mind."

Hemophilia primarily affects young males and managing their disease can be challenging for them and their parents. Shirley Smith of Hariman, Tennessee, has been using the HeliTrax System to manage her 10-year-old son Tyler's severe hemophilia and Factor VIII deficiency since October 2007.

"I love it," says Smith. "As complicated as things are when you have a child with hemophilia, the HeliTrax System just makes life 150 percent easier."

For more information about Helixate FS and HeliTrax please go to or call CSL Behring Consumer Affairs at 1-888-508-6978.

About Helixate(R) FS

Helixate(R) FS is a recombinant factor VIII treatment for hemophilia A that offers convenient administration with a 2.5 mL volume diluent; no available factor VIII product has a smaller diluent size. The 2000 IU vial size requires a 5.0 mL volume diluent.

No albumin is used in the formulation or purification of Helixate FS, and its manufacture includes a solvent/detergent viral inactivation step. The most frequently reported adverse event is local injection-site reaction. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Helixate FS. In 2006, the FDA gave approval for Helixate FS to be stored at room temperature (up to 25C, 77F) for three months. The new storage guidelines for the treatment provide users with greater flexibility and simplify storage options.

Helixate FS is packaged with Mix2Vial, an easy-to-use, plastic, needle-free transfer device with a built-in filter. Use of the Mix2Vial helps minimize the risk of injury and reduces product preparation time.

Helixate(R) FS is manufactured by Bayer HealthCare LLC for CSL Behring LLC.

About Hemophilia

Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 17,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic disease of the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit

Sheila A. Burke, Director, Communications & Public Relations

Worldwide Commercial Operations

CSL Behring


Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
5. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
6. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
7. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
8. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
9. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):